Hypoparathyroidism
MONDO:0001220Hypoparathyroidism is an endocrine disorder in which the parathyroid glands in the neck do not produce enough parathyroid hormone (PTH). Common signs and symptoms include abdominal pain, brittle nails, cataracts, dry hair and skin, muscle cramps, tetany, pain in the face, legs, and feet, seizures, tingling sensation, and weakened tooth enamel (in children). It may be caused by injury to the parathyroid glands (e.g., during surgery). Other causes, include low blood magnesium levels, a side effect of radioactive iodine treatment for hyperthyroidism, metabolic alkalosis, DiGeorge syndrome, and type I polyglandular autoimmune syndrome. The goal of treatment is to restore the calcium and mineral balance in the body.
Also known as: hypoparathyroidism, idiopathic (subtype), parathyroid, underactivity of
68 clinical trials for this condition and its sub-types, 46 tagged with Hypoparathyroidism itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Hypoparathyroidism
-
Hereditary hypoparathyroidism 0 trials · 26 incl. sub-types
3 sub-types
- Familial hypoparathyroidism 0 trials · 10 incl. sub-types Sub-types →
- Pseudohypoparathyroidism 8 trials · 9 incl. sub-types Sub-types →
- Autoimmune polyendocrine syndrome type 1 8 trials
-
Autoimmune hypoparathyroidism 0 trials · 8 incl. sub-types
1 sub-type
Most studied deeper sub-types
-
A gland transplant that could end a lifetime of calcium shots?
Cure CancelledThis trial tests whether transplanting parathyroid glands from a donor can help people with severe hypoparathyroidism—a condition where the body can't regulate calcium, often after neck surgery. Participants are adults aged 18-80 who have had the condition for at least a year and…
Sponsor: University of Alabama at Birmingham • Aim: Cure
Last updated Aug 23, 2026 00:00 UTC
-
MRNA therapy takes on hormone deficiency
Disease control PausedThis early-phase trial tests an mRNA drug called XH02 in 6 adults with hypoparathyroidism, a condition where the body lacks parathyroid hormone (PTH). The drug is designed to instruct cells to produce PTH after being given through a vein. The main goal is to check safety, while a…
Early phase 1 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Sep 21, 2026 17:00 UTC
-
New calcium pill could ease burden for hypoparathyroidism patients
Disease control OngoingThis study tests a new form of calcium called AMOR-1 in 81 adults with hypoparathyroidism, a condition where the body can't control calcium levels. Participants will take either AMOR-1 or standard calcium pills to see if AMOR-1 can better maintain normal calcium levels while allo…
Phase 2 • Sponsor: Amorphical Ltd. • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New drug aims to fix calcium levels in rare genetic disease
Disease control OngoingThis study tests a new drug called encaleret against usual treatments for people with a rare genetic condition called autosomal dominant hypocalcemia type 1 (ADH1), which causes low blood calcium and high urine calcium. About 67 participants will receive either encaleret or stand…
Phase 3 • Sponsor: Calcilytix Therapeutics, Inc., a BridgeBio company • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Heart risk in hypoparathyroidism: could a Once-Daily injection protect arteries?
Disease control OngoingThis study investigates whether long-acting parathyroid hormone (PTH) analogues can reduce signs of early heart and blood vessel damage in adults with chronic hypoparathyroidism. Researchers will compare artery stiffness and heart function in people taking the PTH analogue palope…
Sponsor: National and Kapodistrian University of Athens • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New Once-Weekly shot shows promise for Long-Term hypoparathyroidism control
Disease control OngoingThis study looks at the long-term safety of an experimental drug called MBX 2109 for people with hypoparathyroidism, a condition where the body doesn't produce enough parathyroid hormone. About 60 adults who finished a 12-week phase 2 study will receive weekly injections of MBX 2…
Phase 2 • Sponsor: MBX Biosciences • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New drug could free patients from daily calcium pills
Disease control OngoingThis phase 3 trial tests eneboparatide, a lab-made hormone, in 165 adults with chronic hypoparathyroidism. The goal is to see if it can help patients stop taking high-dose calcium and vitamin D supplements while keeping calcium levels normal. Participants receive either the drug …
Phase 3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New study monitors rare calcium disorder to better understand its long-term effects
Knowledge-focused OngoingThis study is for people with autosomal dominant hypocalcemia types 1 or 2, rare genetic conditions that cause low blood calcium. Researchers will collect past and future health data from 95 participants to learn how the disease changes over time. The goal is to better understand…
Sponsor: Calcilytix Therapeutics, Inc., a BridgeBio company • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:25 UTC
-
Thyroid surgery breakthrough: hormone test may cut complications and hospital stays
Knowledge-focused By invitation onlyThis study looks at whether measuring parathyroid hormone during thyroid removal surgery can help doctors personalize care afterward. About 150 adults having their thyroid removed will be split into groups based on their hormone drop. Some will skip routine blood tests, while oth…
Sponsor: Aarhus University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC